STRO vs TFC
Sutro Biopharma (STRO) versus TFC (TFC) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
TFC (TFC) common stock.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
Latest reported TFC revenue for 2025-12-31 was $24.54B. Net income was $5.31B. Revenue was down 2.1% from 2024-12-31 to 2025-12-31. TFC currently screens at market cap $0.
STRO currently screens at market cap $470.8M. TFC currently screens at market cap $0.
Not investment advice. Open the STRO and TFC stock pages for the full models.
Not investment advice.